DuPont Surges on Earnings Beat as Analysts Lift Targets

DuPont de Nemours has posted its sharpest weekly gain in months, with the stock up 11.5% to $153.46, and the analyst community moving quickly to revise numbers higher after what appears to have been a strong Q3 print.

The post-earnings analyst response is the clearest signal this week. Barclays raised its price target to $176 from $156, maintaining Overweight, in a note filed the morning after results. That reverses the firm's own October initiation target and lifts the bar meaningfully. Fermium Research also bumped its target to $160 from $154 on a Buy rating. The consensus mean now sits at $167.29, implying about 9% further upside from current levels. This follows a period when the Street had been trimming numbers: JPMorgan downgraded the stock to Neutral in early October with a $145 target, and RBC, Citi, and UBS all cut targets during the same stretch. That October defensive repositioning now looks like a low point. The pattern is a classic post-results reset, with cautious analysts who marked down into uncertainty now playing catch-up.

The positioning picture adds texture to the rally. Short interest going into the print was already thin at just over 1% of the free float, and it has barely moved, edging up less than 1% on the week to 4.37 million shares. There is no short-covering story here: shorts were not a meaningful weight on the stock, and the week's gain is not being amplified by a squeeze. The borrow market confirms the same thing. Availability is now at 6,762%, meaning there are roughly 68 shares available to lend for every one currently borrowed, up sharply from around 5,500% a week ago. Cost to borrow is a negligible 0.35%. The lending market is as relaxed as it has been all year. Options positioning has nudged more cautious, with the put/call ratio rising to 0.41, about 1.8 standard deviations above its 20-day average of 0.33. That is a modest signal, likely reflecting traders buying protection against a fade in the post-results move rather than any deep structural concern.

The bull case heading into 2027 rests on Healthcare and Water Technologies continuing to compound at mid-single-digit organic rates, with FCF conversion running above 100% and over $500 million of buybacks planned for the year. The bear case, which JPMorgan's October downgrade put squarely on the table, centres on earnings multiples that still require an 18x to 21x assignment on figures that assume no integration friction, clean spin execution, and a recovery in China and North American electronics demand. At $153.46 and 19.4x trailing earnings, the stock is priced for delivery. The valuation has re-rated sharply: the PE multiple has expanded by roughly 2.6 turns over the past 30 days. The EPS surprise factor score of 22 out of 100 is notably weak, meaning the company has not been a consistent beat relative to peers, which makes the analyst upgrades a function of raised estimates rather than a history of outperformance.

Retail attention has spiked alongside the institutional moves. Wikipedia page views and ORTEX site traffic for the stock registered a combined z-score of 2.35 against the company's own trailing 90-day history as of late October, the highest attention reading in that window. This is a measure of retail interest, not a revenue indicator, but it reflects the stock's growing profile as the year-to-date gain compounds.

3M, the closest US correlated peer, gained 3.2% on the week, a solid move but well below DuPont's 11.5%. The gap reflects company-specific earnings momentum rather than a broad sector lift. What to watch next is whether Barclays' $176 target and the broader analyst reset prompt further institutional accumulation into year-end, or whether the stock consolidates around current levels ahead of the next print, now scheduled for February 9.